ArticleMolecular medicine reports2019
Construction and function of a fusion protein consisting of a single‑chain variable fragment and RBP4.
Article in Molecular medicine reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 1 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Preeclampsia is one of the complications of pregnancy. Often presenting as new‑onset hypertension and proteinuria after 20 weeks of gestation in a previously normotensive patient, it can progress rapidly to serious complications, and is a leading cause of maternal and perinatal mortality. The present study involved the construction of a fusion protein consisting of a single‑chain antibody variable fragment (scFv) and the retinol‑binding protein 4 (RBP4). and investigated the function of this protein. The MaxCodon™ Optimization Program (v13) was used to optimize the amino acid sequence of the scFv‑RBP4 fusion protein and full‑length splice primers were designed by Detai Bio Tech. The scFv‑RBP4 gene was inserted into a proEM expression vector using double digestion, and the accuracy of the final expression vector was confirmed by restriction enzyme digestion and sequencing. The plasmid was transfected into DH5α competent cells and the plasmid was extracted from cells using a transfection reagent. The plasmid and scFv‑RBP4 fusion protein were purified by nickel‑iminodiacetic acid affinity chromatography. Cell proliferation was determined using the Cell Counting Kit‑8 assay and cell invasion was measured using a Transwell invasion assay. The results from the digestion and sequencing showed that the scFv‑RBP4 fusion protein was constructed correctly and that the purity of the target protein was >90%. The scFv‑RBP4 fusion protein was stably expressed in 293T cells. The scFv‑RBP4 fusion protein was extracted from the 293T cells and functional studies were carried out. The scFv‑RBP4 fusion protein significantly increased the invasion, but not the proliferation, of HTR8/SVneo cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.